Featured
Welcome to the third and final episode in our series on the potential of psilocybin-assisted therapy to relieve the existential distress of, and help us live as well as possible with, metastatic breast cancer.
In this episode, we speak with two women taking action to increase legal access to psilocybin-assisted therapy in the United States. The first is a patient living with MBC who, along with her doctor, have brought a lawsuit against the Drug Enforcement Agency which is denying her access to psilocybin in the palliative care setting and under existing Right to Try laws for promising investigational medications for the terminally ill. The patient petitioner, Erinn Baldeschwiler, tells us why she joined the lawsuit, what she hopes to gain from psilocybin-assisted therapy, and what it’s been like to deal with all the legal proceedings on top of a progressing MBC diagnosis.
Our second interview in this episode is with the attorney who is leading the legal case to open access to psilocybin under Right to Try legislation, Kathryn Tucker of the Emerge Law Group. Kathryn explains why psilocybin should be immediately available to patients suffering from distress, anxiety, depression under FDA rules and state and federal Right to Try laws. But the DEA is continuing to block access and hold psilocybin on Schedule 1 of the Controlled Substance Act.
It’s confusing, but we explain it all here. Lastly, see the Episode Notes for a current petition to the DEA to step out of the way and grant access to psilocybin for anyone with a terminal illness.
This series has been led by series producer, Dr. Paula Jayne with assistance from co-host Lynda Weatherby, and senior producer and host Lisa Laudico.
Thanks for listening!
Welcome to the second episode in our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this episode, we talk to two women with breast cancer who had legal access to psilocybin-assisted therapy. Journalist and writer Erica Rex participated in a clinical trial at Johns Hopkins after being diagnosed with early-stage breast cancer. Maari Singfield, a young Canadian woman living with MBC, gained access through an exemption to Section 56(1) of the Canadian Controlled Drugs and Substances Act, a process facilitated by the organization, TheraPsil.
Both women shared with us the process that they went through to gain legal access to psilocybin-assisted therapy, what the treatment was actually like for them, and what, if anything, changed in their lives afterward.
Welcome to our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this first episode, co-host and producer of this series, Dr. Paula Jayne and co-host Lynda Weatherby interview Dr. Boadie Dunlop, Director of the Mood and Anxiety Disorders Program at Emory University. Dr Dunlop shares existing and emerging data on how psilocybin may help those of us living with MBC and discusses an upcoming pilot trial of psilocybin-assisted therapy at Emory University’s Palliative and Supportive Care Clinic.
How does one even begin to bring up the topic of metastatic breast cancer to a child? On this third episode of our MBC & Parenting series, we’ll talk to three experts that can give us some insight and guidance on how to talk with our children in the most open and safe ways. First up, Co-host Martha Carlson and Senior Co-host Victoria Goldberg speak with Dr. Leeza Park, psychiatrist, clinical researcher, and Deputy Director for the Comprehensive Cancer Support Program at the University of North Carolina (UNC) at Chapel Hill. Finally, Senior Co-host and Producer, Lisa Laudico and Co-host Martha Carlson have an illuminating conversation with Morgan Livingstone, Certified Child Life Specialist based in Toronto, Ontario Canada, and Amanda Celeste, Parenting Expert for Project Life, mother, wife, and teacher.
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
All of us approach life and death in general from the perspective of our faith traditions, our family cultures, and the traditions and culture we choose as adults.
What can we, as patients, do to strengthen our communication and relationships with our oncologists? This episode of Our MBC Life, the first in our MBC 101 series, includes perspectives, insights and suggestions from both sides of the critical doctor-patient relationship
How does one do things right at the end of life? There are many ways to answer this question, as varied as all of us.
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.
This is an episode that has something for everyone – not just those of us living with MBC or a terminal diagnosis. It is a privilege to listen to Dr. Boss speak and teach.
The future of personalized care for those living with MBC is already here, and it is happening in Kansas City, Missouri. Dr. Timothy Pluard, Medical Director of the Kansas City’s Saint Luke’s Koontz Center for Advanced Breast Cancer is with us today and we’ll ask him how he and his team create an individualized, completely comprehensive plan for each woman.
This is an interview that doesn’t shy away from the hard conversations that we have when diagnosed with a terminal disease, and gives Lara the opportunity to tell us what it has all felt like for her.
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO